PT - JOURNAL ARTICLE AU - Hiroshi Yotsuyanagi AU - Norio Ohmagari AU - Yohei Doi AU - Takumi Imamura AU - Takuhiro Sonoyama AU - Genki Ichihashi AU - Takao Sanaki AU - Yuko Tsuge AU - Takeki Uehara AU - Hiroshi Mukae TI - Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial) AID - 10.1101/2022.07.15.22277670 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.15.22277670 4099 - http://medrxiv.org/content/early/2022/07/17/2022.07.15.22277670.short 4100 - http://medrxiv.org/content/early/2022/07/17/2022.07.15.22277670.full AB - Background Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a respiratory illness that has led to millions of deaths worldwide and has been declared a pandemic. Most antiviral treatments are targeted toward patients with severe or moderate-to-severe illness or those at high risk of developing severe COVID-19. Limited options exist for patients with mild-to-moderate COVID-19, irrespective of vaccination history or the risk of developing severe illness. Ensitrelvir is a novel oral SARS-CoV-2 3C-like protease inhibitor that has shown promising results in phase 2 studies in treating mild-to-moderate COVID-19. Here we describe the protocol for a phase 3 study designed to evaluate the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19, regardless of risk status or history of vaccination.Methods This is a multicenter, randomized, double-blind, placebo-controlled, phase 3 study. A total of 1590 patients with mild-to-moderate COVID-19 will be enrolled and randomized in 1:1:1 ratio into 3 treatment arms - ensitrelvir 125 mg (375 mg as loading dose on Day 1), ensitrelvir 250 mg (750 mg as loading dose on Day 1), or placebo. Patients will be administered the study interventions orally once daily for 5 days. Treatment outcomes will include efficacy and safety assessments. The primary endpoint will be the time to resolution of COVID-19 symptoms (including 12 symptoms listed in a partially modified index prescribed by the Food and Drug Administration). The three key secondary endpoints will be the change from baseline on Day 4 in the amount of SARS-CoV-2 viral RNA, the time to the first negative SARS-CoV-2 viral titer, and the proportion of participants without resolution of COVID-19 symptoms 3 weeks after administration. All safety assessments and adverse events will be reported.Discussion Time to resolution of COVID-19 symptoms is a suitable endpoint to assess antiviral treatment in these patients. In phase 2a and 2b studies, ensitrelvir has been demonstrated to have antiviral efficacy against SARS-CoV-2 and a trend toward reducing time to resolution of symptoms in patients with mild-to-moderate COVID-19. Through this study, we seek to validate and further establish the clinical efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19.Trial registration Japan Registry of Clinical Trials (https://jrct.niph.go.jp): jRCT2031210350.Competing Interest StatementHY reports consulting fees from Shionogi, lecture fees from Shionogi and ViiV Healthcare, and travel support from Shionogi outside the submitted work. He serves as an advisory board member of Shionogi and President of the Japanese Society of Infectious Diseases. NO declares no conflict of interest. YD reports grants from Shionogi and Entasis; consulting fees from Shionogi, Meiji Seika Pharma, Gilead Sciences, GSK, MSD, Chugai, and bioMerieux; and lecture fees from MSD, AstraZeneca, Shionogi, and Teijin Healthcare outside the submitted work and serves as an advisory board member of FujiFilm. TI, T Sonoyama, GI, T Sanaki, YT, and TU are full-time employees of Shionogi & Co., Ltd. and may own stocks or stock options. HM has received funding relevant to the submitted work from Shionogi and grants from Taisho Pharma; lecture fees from Pfizer, MSD, Shionogi, and Taisho Pharma; and advisory fees from Pfizer, MSD, and Shionogi outside the submitted work.Clinical TrialJapan Registry of Clinical Trials (https://jrct.niph.go.jp): jRCT2031210350.Funding StatementThis study was funded by Shionogi & Co., Ltd. Employees of Shionogi & Co., Ltd. participated in and approved the design and conduct of the study, wrote the protocol, and were involved in the collection, management, analysis, and interpretation of data. Institutional authors reviewed and approved the protocol and collected and interpreted the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was reviewed and approved by the institutional review boards of all participating institutions listed in Supplementary Table. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAEadverse eventCIconfidence intervalCOVID-19coronavirus disease 2019CYP3Acytochrome P450 3AeCRFelectronic case report formRNAribonucleic acidRT-PCRreverse transcription-polymerase chain reactionSAEserious adverse eventSARS-CoV-2severe acute respiratory syndrome coronavirus2 SpO2saturation of percutaneous oxygenVOCvariant of concern